Invivyd, Inc.
IVVD Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$0.59
KIRA · Stoqly’s AI analyst, in plain words
- Invivyd, Inc. had $53.4M of revenue in fiscal 2025, up 110.5% on the year before.
- Its operating margin was −104.0%, up 592.8 pts: of every 100 in sales, about −104 is left after running the business.
- Invivyd, Inc. lost $52.5M in fiscal 2025.
- Free cash flow was −$58.3M in fiscal 2025, −109.1% of revenue.
Market cap
$189M
P/E
—
Revenue
$53.4M
Net income
−$52.5M
Free cash flow
−$58.3M
Operating margin
−104.0%
Invivyd, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+110.5%
Yes. Sales grew 110.5% last year.
Does it make a profit?
−98.2%
No. It lost money last year.
Does profit turn into cash?
−109.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Invivyd, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Invivyd, Inc.
- CIK
- 0001832038
Invivyd, Inc. · IVVD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $25.4M | $53.4M |
| Revenue growth | — | — | — | — | 110.5% |
| Operating margin | — | — | — | −696.8% | −104.0% |
| Net income | −$227M | −$241M | −$199M | −$170M | −$52.5M |
| Net margin | — | — | — | −669.4% | −98.2% |
| Diluted EPS | −$5.32 | −$2.23 | −$1.81 | −$1.43 | −$0.30 |
| Cash | |||||
| Cash from operations | −$185M | −$220M | −$173M | −$170M | −$58.1M |
| Capital expenditure | $0.1M | $1.7M | $0.6M | $0.1M | $0.2M |
| Free cash flow | −$185M | −$222M | −$174M | −$171M | −$58.3M |
| FCF margin | — | — | — | −672.2% | −109.1% |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Share count change | — | 154.0% | 1.2% | 8.2% | 45.3% |
| Debt and strength | |||||
| Cash and short-term investments | $542M | $92.1M | $201M | $69.3M | $227M |
| Shareholders' equity | $558M | $356M | $177M | $67.5M | $242M |
| Current ratio | 9.9x | 15.1x | 4.5x | 1.6x | 7.2x |
| Returns and quality | |||||
| Return on equity | −40.6% | −52.8% | −74.5% | −138.7% | −34.0% |
| Return on tangible equity | −40.6% | −67.8% | −111.9% | −251.6% | −21.7% |
| Piotroski F-score | — | — | — | 1 | 2 |
| Altman Z'' | 11.3 | 10.9 | −8.1 | −28.8 | −0.4 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.5M
5 insiders
Of sales under plans
100%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Invivyd, Inc. · IVVD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.59 a share, the company is worth $189M.
Source: SEC EDGAR XBRL filings (CIK 0001832038). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.